Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial to Evaluate the Impact of XDEMVY on Demodex Blepharitis in Soft Contact Lens Wearers

Trial Profile

Randomized Controlled Trial to Evaluate the Impact of XDEMVY on Demodex Blepharitis in Soft Contact Lens Wearers

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lotilaner (Primary)
  • Indications Blepharitis
  • Focus Therapeutic Use
  • Acronyms Ariel
  • Sponsors Tarsus Pharmaceuticals

Most Recent Events

  • 13 Nov 2024 According to Tarsus Pharmaceuticals media release, results of an ongoing Demodex blepharitis study expected in 2025.
  • 22 Mar 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2024.
  • 22 Mar 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top